<DOC>
	<DOCNO>NCT01136694</DOCNO>
	<brief_summary>The purpose study explore difference productivity loss cost patient treat rheumatoid arthritis ( RA ) biologic disease-modifying antirheumatic drug ( bDMARDs ) compare patient treat conventional DMARDs .</brief_summary>
	<brief_title>Economic Burden Adult Patients Diagnosed With Rheumatoid Arthritis ( RA ) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs ( bDMARDs )</brief_title>
	<detailed_description>Time Perspective : Prospective retrospective analysis claim data</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Evidence bDMARD DMARD identification period ( 01 February 2009 31 July 2009 ) 18 year age old index year At least 12 month continuous enrollment large commercial US health plan affiliate i3 Innovus , include least 6 month 12 month prior index date ( i.e. , preindex period ) least 6 month follow index date ( i.e. , postindex ( followup ) period ) Diagnosis RA ( report baseline survey ) Diagnosis psoriasis , plaque psoriasis , psoriatic arthritis ( ICD9 code 696.0x , 696.1x ) , ankylose spondylitis ( 720.0x ) , Crohn 's disease ( 555.x ) , nonHodgkins lymphoma ( 200.xx , 202.0x202.2x , 202.7x202.8x ) , ulcerative colitis ( 556.x ) position time 18month identification period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>